ANI Pharmaceuticals Q1 2021 Earnings Report
Key Takeaways
ANI Pharmaceuticals reported first quarter 2021 results with net revenues of $54.5 million and net income of $0.1 million. The company is progressing with the Cortrophin Gel sNDA re-filing and the acquisition of Novitium Pharma, while also expanding its branded products portfolio.
Net revenues for Q1 2021 were $54.5 million.
Net income for Q1 2021 was $0.1 million, with diluted earnings per share of $0.01.
Adjusted non-GAAP EBITDA for Q1 2021 was $18.9 million, and adjusted non-GAAP diluted earnings per share was $1.04.
The company is on track for Cortrophin® Gel sNDA re-filing in Q2 2021.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Forward Guidance
The company expects the Novitium transaction and the market opportunity for Cortrophin to be transformational for ANI.
Revenue & Expenses
Visualization of income flow from segment revenue to net income